Illimis Therapeutics Employee Directory

Illimis Therapeutics corporate office is located in 18 Heolleung-ro 569-gil, Seoul, 06376, South Korea and has 11-50 employees.

Employees by Department

Departments

Number of employees

Operations

6

Engineering & Technical

5

C-Suite

2

Illimis Therapeutics CEO

SJ
South Korea flag for contact location.
Suchul JangChief Executive Officer, Illimis Therapeutics (USA)
PhonePhoneEmailEmail
See Profile

Key Employees of Illimis Therapeutics

  • JB
    South Korea flag for contact location.
    Jungu Bae

    Chief Operating Officer

    PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail

Illimis Therapeutics Global Presence

globalPresence illustration
North America1-10
Asia1-10

Index of contact profiles from Illimis Therapeutics

Hundreds of professionals searching for Illimis Therapeutics have connected with key decision-makers. Join them?
Contact Name
Contact Info
Job Title
HQ Location
12

Frequently Asked Questions Regarding Illimis Therapeutics Employees

How many employees does Illimis Therapeutics have?
Illimis Therapeutics has 11-50 employees
Who is the CEO of Illimis Therapeutics?
Illimis Therapeutics’s CEO is Suchul Jang
Who are Illimis Therapeutics key employees?
Some of Illimis Therapeutics key employees are Jungu Bae
Where is Illimis Therapeutics located?
Illimis Therapeutics’s headquarters are located at 18 Heolleung-ro 569-gil, Seoul, 06376, South Korea
How do I contact Illimis Therapeutics?
Illimis Therapeutics Contact Info: Phone number: +82 24456877 Website: www.illimistx.com
What does Illimis Therapeutics do?

Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimers. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from e... xisting antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.Read More

Is Illimis Therapeutics a public company?
Illimis Therapeutics is private company therefore does not currently have an official ticker symbol
See more information about Illimis Therapeutics Employees

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.